

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: InnoCan Pharma Corporation (the "Issuer").

Trading Symbol: INNO

Number of Outstanding Listed Securities: 145,529,690\_\_\_\_\_

Date: June 4, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***The Issuer is focused on the R&D, production and marketing of Health-Tech Innovations for CBD Healthcare and Consumer Lifestyle Products.***

***The Issuer is developing a novel cannabinoid delivery technology with world known scientists, in order to enable the injection of CBD & other cannabinoids.***

***Patent spotlight:***

***REVOLUTIONARY INJECTABLE CBD DELIVERY SYSTEM***

***Oral ingestion of CBD effectiveness is substantially lost via metabolic breakdown. Injection is an ideal delivery method as it would vastly increase the bioavailability of CBD.***

***CBD is an oil substance. However, oils cannot be safely injected. The issuer is working on a solution through research done by an experienced team from the Hebrew University of Jerusalem: a cannabinoid delivery technology enabling the injection of cannabinoids into the blood stream via a unique cannabinoid loaded Liposome Platform Technology ("LPT"). LPT has the potential to become a licensing platform to large pharmaceutical companies for specific cannabinoids / indications.***

**In addition, during the month of May 2020, the Issuer continued its efforts in the development, manufacturing, marketing and distribution of the Issuer branded OTC pharmaceutical products (patent pending), and premium Derma Cosmetic product lines (see also item 5 regarding new research agreement).**

2. Provide a general overview and discussion of the activities of management.

**During the month of May 2020, management continued to support the Issuer's business activity, develop the Issuer's business, and search for global market opportunities, regulatory developments and other strategic business relationships.**

**During the month of May, 2020, the Issuer filed a preliminary short form prospectus in Canada, in connection with a marketed public offering (the "Offering") for gross proceeds of up to CAD \$10,000,000 in units plus a 15% over-allotment option to be co-led by Mackie Research Capital Corporation and Canaccord Genuity Corp. (the "Lead Agents") together with a syndicate that includes Haywood Securities Inc. and PI Financial Corp. (together with the Lead Agents, the "Agents"). The Offering of units will be conducted at a price of CAD 0.18 per unit. Each unit shall be comprised of one common share and one warrant. Each warrant is exercisable into one common share at an exercise price of CAD 0.25 for a period of 36 months following completion of the Short Form Prospectus Offering subject to a warrant acceleration clause.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**On November 5, 2019, the Issuer announced by way of news release that it had signed an agreement with Fancystage Unipessoal LDA of Portugal**

("Fancystage"), to manufacture its cannabidiol (CBD) cosmetic products for the European market. On November 18, 2019, the Issuer announced by way of news release that it had signed an agreement with Biogenesis Inc. of NJ, USA to manufacture its cannabidiol (CBD) cosmetic products for the US market.

Due to the spread of the Corona virus (COVID-19) in many countries around the world, and the significant measures taken by many countries to try to prevent the spread of the Corona virus, the production of the Issuer's products will likely be delayed which will create uncertainty as to the timing of when these products may be distributed and sold in the future. In addition, the measures taken influence the Issuer's marketing abilities, and are expected to affect the future cash flow and sales and revenue of the Issuer.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None to report during the month of May 2020.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**During the month of May 2020, the Issuer entered into letter of intent with Adva Biotechnology Ltd. to develop and produce exosomes for use in its CBD-loaded exosomes (CLX) treatments.**

Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Nothing to report during the month of May 2020.**

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None to report during the month of May 2020.**

7. Describe the acquisition of new customers or loss of customers.

**Nothing to report during the month of May 2020.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**During the month of May 2020, the Issuer filed an international patent application for a novel cannabis-based psoriasis treatment. The patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.**

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None to report during the month of May 2020.**

10. Report on any labour disputes and resolutions of those disputes if applicable.

**None to report during the month of May 2020.**

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**The Issuer is disputing the amounts invoiced by its former legal counsel in December 2019 as they significantly exceed the amounts previously proposed and agreed upon between the parties. To date, no legal claims have been filed and partial amounts have been paid by the Issuer.**

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None to report during the month of May 2020.**

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common shares	217,560	Options Exercise	19,580
Common shares	1,437,661	Issuance to Green Times Consulting Ltd.	N/A
Common shares	8,300	Options Exercise	1,494
Options	400,000	Peter Bloch, a director of the Issuer	N/A

*(1) State aggregate proceeds and intended allocation of proceeds.*

14. Provide details of any loans to or by Related Persons.

**None to report during the month of May 2020.**

15. Provide details of any changes in directors, officers or committee members.

**In May 1, 2020, the Issuer announced the appointment of Professor Daniel Offen, of the Sackler School of Medicine, Sagol School of Neuroscience at Tel Aviv University, to its Scientific Advisory Committee.**

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which may impact the Issuer are detailed in the Issuer's final long form prospectus dated September 13, 2019, under the heading "Risk Factors", which can be viewed under the Issuer's profile on SEDAR ([www.sedar.com](http://www.sedar.com)).

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 4, 2020.

Iris Bincovich

Name of Director or Senior  
Officer



Signature

CEO

Official Capacity

<b>Issuer Details</b> Name of Issuer InnoCan Pharma Corporation	For Month End May 2020	Date of Report YY/MM/D 20/06/4
Issuer Address 1015, 926 – 5 <sup>th</sup> Avenue SW		
City/Province/Postal Code Calgary, Alberta, T2P ON7	Issuer Fax No. ( )	Issuer Telephone No. (403)7771519
Contact Name Nelson Halpern	Contact Position Chief Financial Officer	Contact Telephone No. (433)7771519
Contact Email Address halpern@khmca.ca	Web Site Address <a href="http://www.innocanpharma.com">www.innocanpharma.com</a>	